A phase II study of pembrolizumab (P) in combination with doxorubicin (D) in advanced endometrial cancer (AEC): TOPIC trial/VHIO10001

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorFarinas-Madrid, L.
dc.contributor.authorRubio, M. J.
dc.contributor.authorRedondo, A.
dc.contributor.authorVillacampa Javierre, G.
dc.contributor.authorYubero Esteban, A.
dc.contributor.authorRomero, I.
dc.contributor.authorGil-Martin, M.
dc.contributor.authorGarcia-Donas, J.
dc.contributor.authorGonzalez-Martin, A.
dc.contributor.authorGallego Martinez, A.
dc.contributor.authorGrau, F.
dc.contributor.authorRuiz-Pace, F.
dc.contributor.authorPardo Burdalo, B.
dc.contributor.authorSanchez Lorenzo, M. L.
dc.contributor.authorPiulats, J. M.
dc.contributor.authorOaknin, A.
dc.contributor.authoraffiliation[Farinas-Madrid, L.] Hosp Univ Hebron, Gynaecol Canc Programme Vall dHebron Inst Oncol V, Med Oncol, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
dc.contributor.authoraffiliation[Grau, F.] Hosp Univ Hebron, Gynaecol Canc Programme Vall dHebron Inst Oncol V, Med Oncol, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
dc.contributor.authoraffiliation[Oaknin, A.] Hosp Univ Hebron, Gynaecol Canc Programme Vall dHebron Inst Oncol V, Med Oncol, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
dc.contributor.authoraffiliation[Rubio, M. J.] Hosp Univ Reina Sofia, Med Oncol, Cordoba, Spain
dc.contributor.authoraffiliation[Redondo, A.] Hosp Univ La Paz, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Gallego Martinez, A.] Hosp Univ La Paz, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Villacampa Javierre, G.] Vall dHebron Inst Oncol VHIO, Oncol Data Sci, Barcelona, Spain
dc.contributor.authoraffiliation[Ruiz-Pace, F.] Vall dHebron Inst Oncol VHIO, Oncol Data Sci, Barcelona, Spain
dc.contributor.authoraffiliation[Yubero Esteban, A.] Hosp Clin Univ Lozano Blesa, Med Oncol, Zaragoza, Spain
dc.contributor.authoraffiliation[Romero, I.] Fdn Inst Valenciano Oncol, Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Gil-Martin, M.] Inst Catala Oncol LHosp, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Pardo Burdalo, B.] Inst Catala Oncol LHosp, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Piulats, J. M.] Inst Catala Oncol LHosp, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Garcia-Donas, J.] Hosp Madrid Norte San Chinarro Ctr Integral On, Skin & Rare Tumors Unit, Genitourinary Ginecol Skin & Rare Tumors Unit, Madrid, Spain
dc.contributor.authoraffiliation[Gonzalez-Martin, A.] Univ Navarra Clin, Med Oncol, Grp Espanol Invest Canc Ovario GEICO, Madrid, Spain
dc.contributor.authoraffiliation[Sanchez Lorenzo, M. L.] Univ Navarra Clin, Med Oncol, Madrid, Spain
dc.contributor.funderMSD
dc.date.accessioned2025-01-07T13:41:07Z
dc.date.available2025-01-07T13:41:07Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.1240
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.1240
dc.identifier.urihttps://hdl.handle.net/10668/25750
dc.identifier.wosID700527701263
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.page.numberS761-S762
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleA phase II study of pembrolizumab (P) in combination with doxorubicin (D) in advanced endometrial cancer (AEC): TOPIC trial/VHIO10001
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Reina Sofía

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía